Continuous Lornoxicam Infusion for Orthopaedic Surgery
Status:
Suspended
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
Perioperative continuous infusion of lornoxicam would be an effective and safe regimen to
reduce the patient controlled morphine consumption after orthopaedic surgery.
After ethical approval, 96 patients scheduled for elective orthopaedic fracture surgery under
general anaesthesia were randomly allocated to receive placebo, 12-hourly iv lornoxicam 16 mg
or lornoxicam 16 mg followed with continuous infusion of 1.3 mg/hr., for 48 hours after
surgery (n=32 per group). Anaesthesia was induced with propofol, sufentanil and rocuronium,
and was maintained with 0.5-1 minimum alveolar concentration sevoflurane, sufentanil and
rocuronium. Postoperative patient controlled morphine analgesia was used. Changes in heart
rate, mean blood pressure and sevoflurane minimum alveolar concentration, visual analogue
pain scores, and cumulative patient controlled morphine consumptions and blood loss for 48
hours, platelet functions, bone non-union and the presence of adverse effects were recorded.